Becker's Healthcare April 25, 2024
Mariah Taylor

The FDA approved the first new antibiotic for urinary tract infections in two decades.

The agency approved pivmecillinam tablets for adult women with uncomplicated urinary tract infections caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus, an April 24 FDA news release said.

The approval for Pivya was given to Utility Therapeutics, a U.S. company that acquired the rights to the drug. It is expected to become available in 2025.

In clinical trials, Pivya outperformed placebo (62% vs. 10%) and ibuprofen (66% vs. 22%) for achieving composite response and was comparable to another oral antibacterial...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Pharma, Pharma / Biotech, Provider, Trends
Related Articles:
Opinion: STAT+: How will the Center for Biologics Evaluation and Research change under RFK Jr.?
How the FDA Opens the Door to Risky Chemicals in America’s Food Supply
FDA OKs First Gene Therapy Implant for a Rare Eye Disease
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder
FDA nominee pitches AI application review

Share This Article